Drug Profile
Research programme: neural stem cell delivered oncolytic virus - Therabiologics
Alternative Names: TBX.OncV NSCsLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator TheraBiologics
- Class Oncolytic viruses; Stem cell therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Glioma in USA (Intracerebral) (https://www.google.com/search?q=Therabiologics&sca_esv=562712696&rlz=1C1GCEA_enIN1019IN1019&ei=Fwf3ZLecI66RseMPs6az8AE&ved=0ahUKEwj3g96_pZOBAxWuSGwGHTPTDB4Q4dUDCBA&uact=5&oq=Therabiologics&gs_lp=Egxnd3Mtd2l6LXNlcnAiDlRoZXJhYmlvbG9naWNzMgUQABiABEiWDVDaBFjQCHABeACQAQCYAb4BoAHfBKoBAzAuNLgBA8gBAPgBAcICBRAAGKIE4gMEGAEgQYgGAQ&sclient=gws-wiz-serp)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Glioma in USA (Intracerebral, Injection)
- 16 May 2016 Preclinical trials in Glioma in USA (Intracerebral) before May 2016